Akeso and RemeGen side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Akeso | RemeGen |
|---|---|---|
| Phase 1 | Akeso: 6 of its 17 programs at phase 1
and 1 more — sign in to see them all | 00% |
| Phase 2 | Akeso: 5 of its 17 programs at phase 2
| RemeGen: 5 of its 10 programs at phase 2
|
| Phase 3 | Akeso: 6 of its 17 programs at phase 3
and 1 more — sign in to see them all | RemeGen: 5 of its 10 programs at phase 3
|
| Approved, new studies | 00% | 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akeso8 readouts · 1 phase 3 | Akeso, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Akeso, Dec ’26: 4 programs whose next study reaches primary completion
| · | · | · | · | Akeso, May ’27: 1 program whose next study reaches primary completion
| Akeso, Jun ’27: 1 program whose next study reaches primary completion
| · | · | Akeso, Sep ’27: 1 program whose next study reaches primary completion
| · |
| RemeGen3 readouts · 3 phase 3 | · | RemeGen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3
| · | · | · | · | RemeGen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Akeso
New programs 2
- AK158D1phase 1 · first study · Nov 1
- AK157D1 for injectionphase 1 · first study · Sep 21
Reached a new phase 0
None
Study stopped 1
- cadonilimabphase 2 · terminated Sep 28“Sponsor decision” · NCT05932212
Primary completion later 1
- cadonilimabphase 1 · Nov 2026 → Jun 2028 (+20 mo) · moved Nov 12 · NCT06929663
RemeGen
New programs 2
- telisotuzumab adizutecanphase 2 · first study · Oct 12 · Colorectal Neoplasms
- ABBV-1480phase 2 · first study · Sep 30 · Carcinoma, Non-Small-Cell Lung
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Akeso | RemeGen |
|---|---|---|
| PDCD1 | cadonilimabrule, ivonescimabrule, Anti-PD-1/LAG-3 Bispecific Antibody AK129rule | ABBV-1480, tislelizumabrule |
| VEGFA | ivonescimabrule | ABBV-1480 |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.